This bill amends and reenacts specific sections of Louisiana's controlled substances law, particularly R.S. 40:964, which outlines the composition of various schedules of controlled substances. The bill introduces new substances to Schedule I and Schedule IV, including several fentanyl analogs such as 2',5'-dimethoxyfentanyl and alpha'-methyl butyryl fentanyl, as well as hallucinogenic substances like 4-chloro-2,5-dimethoxyamphetamine and 5-methoxy-alpha-methyltryptamine. Additionally, it adds depressants such as Diclazepam and Flubromazolam to Schedule I and Zuranolone to Schedule IV.

The bill also includes modifications to existing language, such as changing "arylalkylhalide" to "alkylarylhalide" in the definitions of synthetic cannabinoids. The Louisiana State Law Institute is tasked with renumbering the new entries to maintain alphabetical order. Overall, the bill aims to update the state's controlled substances schedules to reflect current drug trends and enhance regulatory measures.

Statutes affected:
HB204 Original: 40:964(S
HB204 Engrossed: 40:964(S
HB204 Enrolled: 40:964(S
HB204 Act 110: 40:964(S